

JOURNAL OF HEPATOLOGY

VOLUME 77, SUPPLEMENT 1, PAGES S1–S1080

CONTENTS

Oral Presentations

General Session I	S1
General Session II	S5
Late-Breaker	S10
Hepatitis C: Clinical aspects and therapy	S15
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness	S18
Non-invasive assessment of liver disease except NAFLD	S22
Immune-mediated and cholestatic: Experimental and pathophysiology	S26
Non-invasive assessment/treatment and liver related outcomes in NAFLD/ALD	S29
Alcoholic liver disease	S33
Fibrosis	S36
NAFLD: Clinical aspects except therapy	S39
Viral hepatitis elimination	S42
Primary Liver Cancer: Experimental and pathophysiology	S45
Cirrhosis and its complications: ACLF and Critical illness	S48
Liver Immunology	S53
Rare liver diseases (including paediatric and genetic)	S58
Nurses and AHP	S63
Gut microbiota in liver disease and liver regeneration	S65
Hepatitis B emerging therapies	S69
NAFLD: Diagnostics and non-invasive assessment	S73
Liver tumours: Clinical aspects except therapy	S75
Public health	S80
Molecular and cellular biology	S83
NAFLD Therapy	S86
Cirrhosis and its complications: Portal Hypertension	S89
Immune-mediated and cholestatic disease: Clinical aspects	S93
Viral hepatitis basic science	S97

Hepatitis B clinical aspects	S100
Cirrhosis and its complications: Experimental and pathophysiology	S103
Liver tumours: Therapy	S107
NAFLD: Experimental and pathophysiology	S111
Liver transplantation and Acute liver failure: Clinical aspects	S114
Poster Presentations	
Alcoholic liver disease	S119
NAFLD: Clinical aspects except therapy	S144
Gut microbiota and liver disease	S173
Immunology	S183
Public Health	S200
Viral hepatitis A/E: Clinical aspects	S269
Viral hepatitis B/D: Clinical aspects except therapy	S271
Immune-mediated and cholestatic disease: Clinical aspects	S305
Cirrhosis and its complications: ACLF and Critical illness	S339
Cirrhosis and its complications: Experimental and pathophysiology	S358
Liver tumours: Therapy	S372
Acute liver failure and drug induced liver injury	S389
NAFLD: Diagnostics and non-invasive assessment	S409
Fibrosis	S463
Non-invasive assessment of liver disease except NAFLD	S495
Nurses and Allied Health Professionals	S509
Rare liver diseases (including paediatric and genetic)	S513
Viral hepatitis C: Clinical aspects except therapy	S541
Viral Hepatitis C: Post SVR and long term follow up	S561
Viral hepatitis C: Therapy and resistance	S579
Immune-mediated and cholestatic: Experimental and pathophysiology	S599
Cirrhosis and its complications: Portal Hypertension	S608
Liver tumours: Experimental and pathophysiology	S636
NAFLD: Experimental and pathophysiology	S665
NAFLD: Therapy	S713
Liver development, physiology and regeneration	S734
Molecular and cellular biology	S745
Liver transplantation and hepatobiliary surgery: Clinical aspects	S767
Liver transplantation and hepatobiliary surgery: Experimental and pathophysiology	S818
Viral hepatitis B/D: therapy	S823
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness	S882

Liver tumours: Clinical aspects except therapy	S912
Author Index	S940
Disclosures: no commercial relationships	S1021
Disclosures: commercial relationships	S1065
Reviewers list	S1080

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004; 351:1250–1251 and *New Engl J Med* 2005; 352:2437–2438.

Available online at www.sciencedirect.com

